Biotech firms are turning to artificial intelligence to boost productivity and address talent shortages. Insilico Medicine is building a multi‑task AI platform that can generate disease hypotheses, design candidate molecules and even repurpose existing drugs, aiming to speed drug discovery and cut costs. GenEditBio is using AI to design engineered protein delivery vehicles that target specific tissues for in‑vivo CRISPR therapy, recently receiving FDA clearance for a corneal‑dystrophy trial. Both companies stress the need for richer, more diverse data to improve model accuracy and envision future tools such as digital twins for virtual clinical testing. Leer más →

AlphaFold, the artificial‑intelligence system created by DeepMind, has moved from early work on games to becoming a cornerstone of modern biology. Its breakthrough version, AlphaFold2, achieved atomic‑level protein structure predictions, leading to a public database that now holds predictions for the entire known protein universe. Researchers worldwide—millions in hundreds of countries—use the resource daily, and the technology continues to expand into DNA, RNA and drug design through AlphaFold 3. While the system faces challenges such as hallucinations in disordered regions, DeepMind is pairing generative models with rigorous verification and developing multi‑agent AI co‑scientists to further accelerate discovery. Leer más →

Onepot AI, founded by Daniil Boiko and Andrei Tyrin, has raised $13 million in a seed round led by Fifty Years, with participation from Khosla Ventures, Speedinvest, OpenAI co‑founder Wojciech Zaremba and Google chief scientist Jeff Dean. The company tackles a long‑standing bottleneck in drug discovery—chemical synthesis—by pairing a dedicated lab (POT‑1) with an AI‑driven organic chemist named Phil. Boiko and Tyrin aim to compress months‑long synthesis timelines into days, expanding the design space for biotech and pharma partners while building a second lab in San Francisco. Leer más →

A joint effort by Google and Yale University has produced a 27‑billion‑parameter AI model, called Gemma, that can identify drugs capable of turning "cold" tumors visible to the immune system. The model evaluated 4,000 compounds, pinpointing both known agents and unexpected candidates. In laboratory tests, a combination of interferon and the AI‑selected drug silmitasertib boosted antigen presentation, effectively exposing previously hidden cancer cells. Researchers say the discovery could lead to earlier detection and new therapeutic strategies for cancers that often evade diagnosis. Leer más →